US Patent 11623960 Dual-function antibodies targeting VEGFR2 and VEGFR3
Patent 11623960 was granted and assigned to National Health Research Institutes on April, 2023 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 11623960 Dual-function antibodies targeting VEGFR2 and VEGFR3
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.